Role of everolimus in the treatment of metastatic HER2-negative/HR-positive breast cancer
出版年份 2017 全文链接
标题
Role of everolimus in the treatment of metastatic HER2-negative/HR-positive breast cancer
作者
关键词
-
出版物
Future Oncology
Volume 13, Issue 16, Pages 1371-1384
出版商
Future Medicine Ltd
发表日期
2017-04-26
DOI
10.2217/fon-2017-0098
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Dosing and Safety Implications for Oncologists When Administering Everolimus to Patients With Hormone Receptor-Positive Breast Cancer
- (2016) Hope S. Rugo Clinical Breast Cancer
- Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From BOLERO-2
- (2016) Gabriel N. Hortobagyi et al. JOURNAL OF CLINICAL ONCOLOGY
- A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer
- (2015) Daniele Generali et al. BREAST CANCER RESEARCH AND TREATMENT
- Recent advances in the treatment of hormone receptor positive HER2 negative metastatic breast cancer
- (2015) Palma Fedele et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Targeted therapy in her2-positive metastatic breast cancer: a review of the literature
- (2015) X. Zhu et al. Current Oncology
- Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial
- (2015) Sara A Hurvitz et al. LANCET ONCOLOGY
- Real-world effectiveness of everolimus-based therapy versus fulvestrant monotherapy in HR+/HER2- metastatic breast cancer
- (2015) Yanni Hao et al. Journal of Comparative Effectiveness Research
- Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2
- (2015) Gabriel N. Hortobagyi NEOPLASIA
- Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer
- (2014) M. Aapro et al. ANNALS OF ONCOLOGY
- Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2
- (2014) H. S. Rugo et al. ANNALS OF ONCOLOGY
- Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer
- (2014) I. Treilleux et al. ANNALS OF ONCOLOGY
- Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†
- (2014) M. Piccart et al. ANNALS OF ONCOLOGY
- A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: An analysis of the ATHENA trial
- (2014) Antonio Llombart-Cussac et al. BREAST
- Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial
- (2014) Vakaramoko Diaby et al. BREAST CANCER RESEARCH AND TREATMENT
- Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2–Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
- (2014) Ann H. Partridge et al. JOURNAL OF CLINICAL ONCOLOGY
- Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
- (2014) Fabrice André et al. LANCET ONCOLOGY
- The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers
- (2014) Elisavet Paplomata et al. Therapeutic Advances in Medical Oncology
- Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
- (2013) Denise A. Yardley et al. ADVANCES IN THERAPY
- Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2
- (2013) J. Thaddeus Beck et al. BREAST CANCER RESEARCH AND TREATMENT
- Comparative efficacy of everolimus plus exemestane versus fulvestrant for hormone-receptor-positive advanced breast cancer following progression/recurrence after endocrine therapy: a network meta-analysis
- (2013) Thomas Bachelot et al. BREAST CANCER RESEARCH AND TREATMENT
- Endocrine Resistance in Breast Cancer: Focus on the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Pathway
- (2013) Shira Peleg Hasson et al. Breast Care
- Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial
- (2013) Howard A. Burris et al. CANCER
- Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptor–Positive Breast Cancer in BOLERO-2
- (2013) Kathleen I. Pritchard et al. Clinical Breast Cancer
- Bone effects of mammalian target of rapamycin (mTOR) inhibition with everolimus
- (2013) Peyman Hadji et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup analysis from the BOLERO-2 study
- (2013) Mario Campone et al. EUROPEAN JOURNAL OF CANCER
- Effect of Everolimus on Bone Marker Levels and Progressive Disease in Bone in BOLERO-2
- (2013) M. Gnant et al. JNCI-Journal of the National Cancer Institute
- Demystifying trial networks and network meta-analysis
- (2013) E. J. Mills et al. BMJ-British Medical Journal
- Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2012) F. Cardoso et al. ANNALS OF ONCOLOGY
- Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
- (2012) Thomas Bachelot et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting Angiogenesis in Metastatic Breast Cancer
- (2012) S. Reddy et al. ONCOLOGIST
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus
- (2010) P. J. Houghton CLINICAL CANCER RESEARCH
- Overall Survival and Post-Progression Survival in Advanced Breast Cancer: A Review of Recent Randomized Clinical Trials
- (2010) Everardo D. Saad et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
- (2010) Jack Cuzick et al. LANCET ONCOLOGY
- Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study
- (2009) John F.R. Robertson et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
- (2009) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor–Positive Breast Cancer
- (2009) José Baselga et al. JOURNAL OF CLINICAL ONCOLOGY
- Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival
- (2009) Kristine R. Broglio et al. JNCI-Journal of the National Cancer Institute
- S6 Kinase 1 Regulates Estrogen Receptor α in Control of Breast Cancer Cell Proliferation
- (2008) Rachel L. Yamnik et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Identifying Optimal Biologic Doses of Everolimus (RAD001) in Patients With Cancer Based on the Modeling of Preclinical and Clinical Pharmacokinetic and Pharmacodynamic Data
- (2008) Chiaki Tanaka et al. JOURNAL OF CLINICAL ONCOLOGY
- Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors
- (2008) Josep Tabernero et al. JOURNAL OF CLINICAL ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now